全文获取类型
收费全文 | 87857篇 |
免费 | 7992篇 |
国内免费 | 6520篇 |
专业分类
耳鼻咽喉 | 707篇 |
儿科学 | 918篇 |
妇产科学 | 1057篇 |
基础医学 | 10773篇 |
口腔科学 | 1648篇 |
临床医学 | 12034篇 |
内科学 | 13222篇 |
皮肤病学 | 834篇 |
神经病学 | 4781篇 |
特种医学 | 3204篇 |
外国民族医学 | 61篇 |
外科学 | 8550篇 |
综合类 | 14963篇 |
现状与发展 | 30篇 |
一般理论 | 3篇 |
预防医学 | 5227篇 |
眼科学 | 2546篇 |
药学 | 9082篇 |
68篇 | |
中国医学 | 4792篇 |
肿瘤学 | 7869篇 |
出版年
2024年 | 316篇 |
2023年 | 1641篇 |
2022年 | 3845篇 |
2021年 | 4670篇 |
2020年 | 3493篇 |
2019年 | 3052篇 |
2018年 | 3130篇 |
2017年 | 2871篇 |
2016年 | 2612篇 |
2015年 | 4125篇 |
2014年 | 4918篇 |
2013年 | 4183篇 |
2012年 | 6302篇 |
2011年 | 7126篇 |
2010年 | 4271篇 |
2009年 | 3256篇 |
2008年 | 4189篇 |
2007年 | 4484篇 |
2006年 | 4414篇 |
2005年 | 4540篇 |
2004年 | 2785篇 |
2003年 | 2546篇 |
2002年 | 2217篇 |
2001年 | 1904篇 |
2000年 | 2142篇 |
1999年 | 2497篇 |
1998年 | 1663篇 |
1997年 | 1582篇 |
1996年 | 1211篇 |
1995年 | 1057篇 |
1994年 | 885篇 |
1993年 | 603篇 |
1992年 | 713篇 |
1991年 | 609篇 |
1990年 | 551篇 |
1989年 | 474篇 |
1988年 | 392篇 |
1987年 | 349篇 |
1986年 | 247篇 |
1985年 | 190篇 |
1984年 | 92篇 |
1983年 | 76篇 |
1982年 | 41篇 |
1981年 | 45篇 |
1980年 | 29篇 |
1979年 | 30篇 |
1965年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
Rationale:The treatment of dilated cardiomyopathy (DCM) has recently been greatly improved, especially with the widespread use of sacubitril/valsartan (ARNI) combination therapy. We know that ARNI-like drugs can significantly improve the symptoms of heart failure with reducing ejection fraction. However, clinical studies evaluating the safety and efficacy of ARNI in DCM-associated arrhythmia are limited, and whether individuals with arrhythmia would benefit from ARNI remains controversial. In this case, we report a patient with complete left bundle branch block (CLBBB) associated with DCM whose CLBBB returned to normal after treatment with ARNI.Patient concerns:A 38-year-old man was admitted to the hospital for 20 days for idiopathic paroxysmal dyspnea. He presented with exacerbated dyspnea symptoms at night, accompanied by cough and sputum.Diagnosis:Physical examination revealed a grade 4/6 systolic murmur could be heard in the apical area of the heart and mild edema was present in both lower limbs. Laboratory examination found that the B-type natriuretic peptide was significantly increased. Echocardiography indicated left atrial internal diameter, right ventricular internal diameter, and left ventricular diastolic diameter were enlarged and ejection fraction was significantly decreased. Besides, the pulsation of the wall was diffusely attenuated. Electrocardiogram was suggestive of tachycardia and CLBBB. A diagnosis of DCM with CLBBB was considered based on a comprehensive evaluation of the physical examination, laboratory examination, echocardiography and electrocardiogram.Interventions:The patient was treated with ARNI at a dose of 50 mg (twice a day) at first, gradually increasing to the target dose (200 mg, twice a day) in the following 9 months as shown in Table Table1,1, along with metoprolol 25 mg (once a day [qd]), diuretics 20 mg (qd), and aldosterone 20 mg (qd).Table 1Specific medications used in treatment.
Open in a separate windowARNI = sacubitril/valsartan, QD = once a day.Outcomes:After treatment with ARNI during the 9-month follow-up, the patient’s symptoms improved, and CLBBB returned to normal.Lessons:Clinical studies evaluating the safety and efficacy of ARNI in DCM-associated arrhythmia are limited, and whether individuals with arrhythmia would benefit from ARNI remains controversial. This report will help to instruct the clinical treatment of DCM patients with CLBBB and the potential application of ARNI. 相似文献
Month(s) and dates after discharge | Morning (ARNI) | Night (ARNI) | Metoprolol 23.75 mg QD; diuretics (furosemide) 20 mg QD; aldosterone 20 mg QD |
---|---|---|---|
Month 1 (28/02/20–27/03/20) | 50 mg | 50 mg | |
Month 2 (27/03/20–26/04/20) | 100 mg | 50 mg | |
Month 3–4 (26/04/20–28/06/20) | 100 mg | 100 mg | |
Months 5–7 (28/05/20–29/08/20) | 150 mg | 100 mg | |
Months 8–11 (29/08/20–13/11/20) | 150 mg | 150 mg | |
Month 11–present (13/11/20–) | 200 mg | 200 mg |
994.
Background:The 2020 European Society of Cardiology guidelines do not recommend pretreatment for nonST-segment elevation myocardial infarction (NSTEMI) patients with unclear coronary anatomy, which is inconsistent with our routine preoperative approach to loading P2Y12 receptor inhibitors (e.g., preoperative loading of 300 mg of clopidogrel).Objectives:The purpose of our study was to compare the safety and effectiveness of P2Y12 inhibitors administered before coronary angiography or at least before percutaneous coronary intervention (PCI) with during or after PCI.Methods:Cochrane, PubMed, and Embase databases were searched. The primary effect endpoint and safety endpoint were any-cause death and major bleeding, respectively. Major adverse cardiovascular events, myocardial infarction and revascularization were also analyzed.Results:Our search identified 9 trials. P2Y12 inhibitor pretreatment was associated with lower death from any cause (OR 0.62, 95% CI 0.53–0.72, P < 0.00001) without increasing the risk of bleeding (OR 1.02, 95% CI 0.80–1.30, P = 0.89). However, prasugrel or ticagrelor pretreatment was not associated with a lower risk of mortality (OR 0.70, 95% CI 0.31–1.59, P = 0.40) and increased the risk of bleeding (OR 1.67, 95% CI 1.10–2.54, P = 0.02).Conclusions:In summary, clopidogrel pretreatment was associated with significantly lower mortality, major adverse cardiovascular events, myocardial infarction and revascularization with no increase in major bleeding. However, these advantages were not observed with prasugrel or ticagrelor pretreatment. 相似文献
995.
Min Li Tianjiao Zhang Jing Zhu Yuebo Li Wenying Chen Yanhu Xie Wei Zhang Rongzhu Chen Wei Wei Guihong Wang Jiwei Qin Weidong Zhao Dabao Wu Zhen Shen Bjrn Nashan Ying Zhou 《Oncology Letters》2022,23(5)
The present study aimed to evaluate the postoperative complications and the impact of an enhanced recovery programme in patients who underwent primary surgery (including extensive upper abdominal surgery) for epithelial ovarian carcinoma (EOC). All patients with stage I–IV ovarian carcinoma who underwent primary surgery were identified, and postoperative complications were evaluated and graded according to the Clavien-Dindo classification. Of 161 patients, 46 (28.57%) underwent surgical staging, 27 (16.77%) standard cytoreduction, 12 (7.45%) en bloc debulking and 76 (47.20%) extraradical debulking. A total of 157 patients (97.52%) achieved optimal tumor reduction (<1 cm). The mean postoperative hospitalization time was 17.33±11.29 days after completion of the initial postoperative chemotherapy (IPC), and the IPC interval was 16.22±10.09 days. A total of 13 patients (8.07%) had grade 3 complications (9 with wound dehiscence, 3 with digestive tract leakage and 1 with a bladder fistula). A total of 2 patients (1.24%) had grade 4–5 complications [1 patient with severe pneumonia returned to the intensive care unit (ICU) for tracheotomy and respiration rehabilitation; the other patient died of septicemia on day 19]. The multivariate analysis of the preoperative factors revealed that a human epididymis protein 4 (HE4) level of ≥717 pM (P=0.015) and Federation International of Gynecology and Obstetrics (FIGO) stage IV (P=0.004; compared with stage IIIC) were associated with grade 3–5 complications. The bootstrap analysis revealed that a cancer antigen 125 (CA125) level of ≥1,012 U/ml (P=0.034), a HE4 level of ≥717 pM (P=0.007) and FIGO stage IV (P=0.002; compared with stage IIIC) were significantly associated with grade 3–5 complications. Meanwhile, the multivariate analysis of the postoperative factors did not reveal any risk factors associated with grade 3–5 complications; the bootstrap analysis revealed that only transfer to the ICU after surgery (P=0.026) was significantly associated with grade 3–5 complications. In conclusion, the study found that application of enhanced recovery after surgery protocols is feasible in patients with EOC, especially in those undergoing advanced extensive upper abdominal surgery, and CA125, HE4 and FIGO stage IV were related with the occurrence of adverse perioperative outcomes. 相似文献
996.
997.
增智开窍针法对孤独症儿童语言功能的干预作用 总被引:2,自引:0,他引:2
目的观察针刺治疗儿童孤独症的临床疗效。方法采用增智开窍针法,选用孤独症治疗评估量表(ATEC),对32例患儿临床症状进行检测评估。结果针刺治疗后语言交流、人际关系、动作行为、个人能力均有改善,其中语言交流的显效率与其他三项比较,差异有统计学意义(P〈0.05);治疗前后ATEC评定结果比较,语言项P〈0.01,社交项、感知项、行为项针刺前后比较P〈0.05,差异均有统计学意义。结论针刺能有效改善儿童孤独症患儿的临床症状,对语言功能的干预作用尤为明显。 相似文献
998.
植物化感作用及其在中药材栽培中的应用 总被引:1,自引:0,他引:1
本文介绍了目前植物化感作用的研究领域及其进展,包括化感物质的收集、分离和鉴定,化感物质作用机理以及影响化感作用的因素等方面,分析了药用植物化感作用较为严重的原因以及在栽培过程中追求药材质量的同时很可能会加剧其化感作用的特点,并且从栽培措施、化感育种以及改善土壤微生态环境等几个方面提出了有效利用和克服药用植物化感作用的措施,旨在为中药材规范化种植提供理论和方法依据。 相似文献
999.
Yaqing Zhou Limei Jia Baojin Lu Long Bai Wei Cui 《Journal of clinical hypertension (Greenwich, Conn.)》2022,24(7):898
A simple renal cyst (SRC) may increase the risk for hypertension. The authors examined the relationship between a SRC and hypertension in participants receiving physical examinations at Hebei Medical University. This study enrolled 66 883 participants who received physical examinations at our center from January 2012 to December 2017. Demographic data, medical history related to hypertension, hematological indexes, hypertension, and SRC subtype based on ultrasound examinations were examined. The relationship between SRC and hypertension was analyzed using univariate and multivariate logistic regression analysis in different models. Subgroup analysis and propensity score (PS) matching were also performed. Based on SRC subtype (unitary vs. multiple, small vs. large, unilateral vs. bilateral), a comprehensive scoring system was established to determine the effect of SRC load on hypertension. The results of univariate and multivariate analysis indicated that SRC was a risk factor for hypertension (P < .01). Subgroup and interaction analysis showed the homogeneity that SRC was an independent risk factor for hypertension in multiple subgroups (P > .05). A SRC remained an independent risk factor for hypertension after PS matching (P < .01). Based on a scoring system that considered different SRC subtypes, the risk for hypertension increased with renal cyst load (P < .01). In conclusions, a SRC was an independent risk factor for hypertension, and there was a positive correlation between SRC load and hypertension. The risk of hypertension increased gradually with the size, number, and location of a SRC. Careful follow‐up or excision should be considered for patients with SRCs. 相似文献
1000.
Yuan Hong Ziyi Zhou Nan Zhang Qiangqiang He Zhangyou Guo Lishun Liu Yun Song Ping Chen Yaping Wei Qiuyue Xu Ya Li Binyan Wang Xianhui Qin Xiping Xu Yong Duan 《Journal of clinical hypertension (Greenwich, Conn.)》2022,24(7):945
We aimed to evaluate the prospective association of vitamin B5 with all‐cause mortality and explore its potential modifiers in Chinese adults with hypertension. A nested, case‐control study was conducted in the China Stroke Primary Prevention Trial, including 505 deaths of all causes and 505 matched controls. The median follow‐up duration was 4.5 years. The primary outcome measure in this investigation was all‐cause mortality, which encompassed deaths for any reason. The mean plasma vitamin B5 concentration for cases (43.7 ng/mL) was higher than that in controls (40.9 ng/mL) (p = .001). When vitamin B5 was further assessed as quintiles, compared with the reference group (Q1: < 33.0 ng/mL), the risk of all‐cause mortality increased by 29% (OR = 1.29, 95% CI: 0.83‐2.01) in Q2, 22% (OR = 1.22, 95% CI: 0.77‐1.94) in Q3, 62% (OR = 1.62, 95% CI: 1.00‐2.62) in Q4, and 77% (OR = 1.77, 95% CI: 1.06‐2.95) in Q5. The trend test was significant (p = .022). When Q4‐Q5 were combined, a significant 41% increment (OR = 1.41, 95% CI: 1.03‐1.95) in all‐cause death risk was found compared with Q1‐Q3. The adverse effects were more pronounced in those with normal folate levels (p‐interaction = .019) and older people (p‐interaction = .037). This study suggests that higher baseline levels of plasma vitamin B5 are a risk factor for all‐cause mortality among Chinese patients with hypertension, especially among older adults and those with adequate folate levels. The findings, if confirmed, may inform novel clinical and nutritional guidelines and interventions to optimize vitamin B5 levels. 相似文献